(Q45191163)

10 December 2017

0 references

Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens (English)

1 reference

10 December 2017

1 reference

G Hoeffken

1

1 reference

10 December 2017

D Talan

2

1 reference

10 December 2017

L S Larsen

3

1 reference

10 December 2017

S Peloquin

4

1 reference

10 December 2017

S H Choudhri

5

1 reference

10 December 2017

D Haverstock

6

1 reference

10 December 2017

P Jackson

7

1 reference

10 December 2017

D Church

8

1 reference

10 December 2017

publication date

1 October 2004

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

10 December 2017

published in

1 reference

10 December 2017

volume

23

1 reference

10 December 2017

issue

10

1 reference

10 December 2017

page(s)

772-775

1 reference

The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection

10 December 2017

cites work

1 reference

12 December 2020

Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group

1 reference

12 December 2020

Guidelines for community-acquired pneumonia: a tale of 2 countries

1 reference

12 December 2020

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

1 reference

12 December 2020

The epidemiology of community-acquired pneumonia among hospitalized adults

1 reference

12 December 2020

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults

1 reference

12 December 2020

A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia

1 reference

12 December 2020

Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines

1 reference

12 December 2020

Severe community-acquired pneumonia. Risk factors and follow-up epidemiology.

1 reference

12 December 2020

Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association

1 reference

12 December 2020

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

12 December 2020

Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia

1 reference

12 December 2020

Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course

1 reference

12 December 2020

Importance of atypical pathogens of community-acquired pneumonia

1 reference

12 December 2020

10.1007/S10096-004-1214-5

Identifiers

DOI

1 reference

Dimensions Publication ID

10 December 2017

1002798999

0 references

1 reference